Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
CTX-712 · 1 trial · 2 indications
MTD is the dose producing \<33% of dose-limiting toxicities.
| Arm | Type | Description |
|---|---|---|
| Dose Escalation Cohort | EXPERIMENTAL | Drug: CTX-712 administered at 20 mg, 40 mg, 80 mg, 100 mg, 140 mg weekly, or 60 mg, 80 mg, 100 mg twice a week |
| Initial Expansion Cohort | EXPERIMENTAL | Drug: CTX-712 administered at a dose to be determined from the data of dose escalation cohort |
| Phase 2 | EXPERIMENTAL | CTX-712 administered at the recommended dose by the expansion cohort |
| Name | Type | Description |
|---|---|---|
| CTX-712 | DRUG | CTX-712 will be provided as a 20 mg tablet for oral administration. Patients will take CTX-712 once or twice weekly, depending on their dose level assignment, during each 28-day cycle. |
Inclusion criteria: 1. Age ≥18 years. 2. Diagnosis of AML, HR-MDS, or high marrow blast MDS/MPN (including CMML). Note: Only patients with AML and HR-MDS are eligible in the expansion cohorts. 3. Prior treatment history must include 1-4 prior lines of therapy. Note: 1-3 prior lines are allowed for ...
CTX-712 is an investigational small molecule being developed for the treatment of Acute Myeloid Leukemia (AML). It is also being studied in higher risk Myelodysplastic Syndromes (MDS). The drug is currently in Phase 1 clinical development and is not yet approved by regulatory authorities.
CTX-712 is being developed by cbdMD, Inc., a company traded on the stock exchange under the ticker symbol YCBD. The company is conducting clinical research on this investigational oncology drug candidate.
CTX-712 is currently in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by the FDA or other regulatory agencies. The drug is being studied in a Phase 1 trial for relapsed or refractory Acute Myeloid Leukemia and higher risk Myelodysplastic Syndromes.
CTX-712 is being studied in a Phase 1 clinical trial with the identifier NCT05732103. This trial is recruiting participants in the United States and is investigating the drug in patients with relapsed or refractory Acute Myeloid Leukemia and higher risk Myelodysplastic Syndromes. The trial has a planned enrollment of 225 participants.
CTX-712 is the primary name for this investigational drug candidate. No alternative names have been reported for this compound. It is a small molecule being developed for oncology indications, specifically Acute Myeloid Leukemia and Myelodysplastic Syndromes.